Evidence for Naltrexone in Self-Harm: Not Recommended as Primary Treatment
Naltrexone is not recommended as a primary pharmacological intervention for self-harm behaviors in young people or adults, as there are no published trials specifically evaluating its efficacy for preventing self-harm or suicide, and current guidelines do not support pharmacotherapy solely for this indication. 1
Current Guideline Recommendations
The most recent and authoritative guidance from the 2025 practitioner review explicitly states that pharmacotherapy is not recommended solely for the prevention of self-harm or suicide in young people 1. The 2011 WHO guidelines for self-harm management make no mention of naltrexone, instead recommending:
- Structured problem-solving approaches
- Regular contact with healthcare providers
- Social support facilitation
- Restricting access to means of self-harm 2
These psychosocial interventions form the evidence-based foundation for self-harm treatment, not pharmacological agents.
The Naltrexone Evidence Gap
While naltrexone has FDA approval for alcohol dependence (50 mg daily) and opioid dependence 3, no systematic evidence exists for its use in self-harm behaviors specifically. The available research addresses different populations:
Self-Injurious Behavior in Autism (Not Self-Harm)
The research on naltrexone primarily involves self-injurious behavior (SIB) in autism and developmental disabilities, which is neurobiologically distinct from deliberate self-harm:
- A 2024 review found that naltrexone 25-50 mg/day may decrease self-injurious behaviors in this specific population 4
- A 2004 meta-analysis showed 80% of subjects with developmental disabilities improved on naltrexone, with 47% experiencing ≥50% reduction in SIB 5
- Doses studied ranged from 0.5-2 mg/kg/day, with transient sedation as the most common adverse effect 6
Critical distinction: Self-injurious behavior in autism is thought to involve endogenous opioid dysregulation and is fundamentally different from the emotional dysregulation and interpersonal factors driving deliberate self-harm in psychiatric populations.
Safety Considerations from FDA Labeling
The FDA label for naltrexone reveals important safety concerns relevant to self-harm populations 3:
Depression and suicidality monitoring is mandatory:
- Depression rates in trials: 0-15% with naltrexone vs 0-17% with placebo
- Suicide attempt/ideation: 0-1% with naltrexone vs 0-3% with placebo
- "Physicians should be aware that treatment with naltrexone does not reduce the risk of suicide in these patients" 3
Hepatotoxicity risk:
- Doses above 50 mg/day cause hepatocellular injury in a substantial proportion of patients
- Baseline and periodic liver function monitoring required 3
Contraindications:
- Cannot be used with opioid medications (will precipitate withdrawal or block analgesia)
- Requires 7-10 day opioid-free period before initiation 3
The "Low-Dose" Naltrexone Confusion
Some literature discusses "low-dose naltrexone" (LDN, 1-5 mg daily) for various conditions including fibromyalgia and Crohn's disease 7. This is distinct from the 25-50 mg doses studied for self-injurious behavior in autism 4. There is no evidence base for LDN specifically in self-harm, and the proposed mechanisms (glial modulation, Toll-like receptor 4 signaling) are speculative for this indication.
What Should Be Done Instead
For patients presenting with self-harm:
Comprehensive mental health assessment by a qualified professional after any self-harm episode resulting in hospital presentation 1
Evidence-based psychotherapy:
Treat underlying psychiatric conditions with appropriate medications:
Regular follow-up contact (telephone, home visits, letters) for persons with recent self-harm 2
Family involvement wherever possible, carefully tailored to context 1
Restrict access to means of self-harm 2
Clinical Bottom Line
There is no role for naltrexone in the treatment of deliberate self-harm behaviors. The evidence base is absent, guidelines do not support it, and the FDA label explicitly warns that naltrexone does not reduce suicide risk. Clinicians should focus on evidence-based psychosocial interventions and treatment of underlying psychiatric disorders rather than pursuing off-label pharmacological approaches without supporting data.
The confusion likely arises from conflating self-injurious behavior in autism (where some evidence exists) with deliberate self-harm in psychiatric populations (where no evidence exists). These are distinct phenomena requiring different treatment approaches.